| BSN Rank:
3 / 127
(What's this?) |
|
Accomplish Score: 12520
|
|
Popularity Score: 9
|
|
# in My Circle: 0
|
|
# in My Org(s): 337
|
| We'll Post Your CV for Free! |
| |
| |
|
Speaking/Presenting-Abstract/Poster at Mtg: 712 (9256 / 3)
|
|
| |
|
Honors and Awards: 45 (450 / 0)
|
-
Tier I Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy (2001 - Present)
-
Keynote Lectureship Series (2010)
-
Keynote Lecture (2009)
|
| |
|
Clinical Trial Activity: 5 (45 / 0)
|
-
Treatment of relapsed and refractory non-Hodgkin=s lymphoma with continuous low dose cyclophosphamide and Celebrex: a multicentre phase II study (2001)
-
Pilot study of low dose chemotherapy and cyclo-oxygenase-2 inhibitor as anti-angiogenic therapy in children with progressive or recurrent solid tumors (2001)
-
APhase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressive advanced renal cell carcinoma (2001)
|
| |
|
Grant Support: 17 (153 / 0)
|
-
Translational studies of metronomic chemotherapy and antiangiogenic drugs for metastatic disease (2010)
-
Host cell assisted primary and metastatic tumor regrowth after chemotherapy (2009)
-
Surrogate molecular biomarkers for antiangiogenic receptor tyrosine kinase inhibitory drugs (2007)
|
| |
|
Patents Pending: 2 (16 / 0)
|
-
Methods for enhancing the efficacy of vascular damaging agents. (2007)
-
Treatment, diagnosis and evaluation of anticancer therapy resistance in melanoma (Trp 2). (2003)
|
| |
|
Journal - Editor/Reviewer: 17 (119 / 0)
|
-
International Journal of Cancer (2009)
-
Current Cancer Drug Targets (2006)
-
Angiogenesis (1998 - 2006)
|
| |
|
Peer Reviewed Papers, Books, Chapters: 248 (1488 / 0)
|
-
Anti-Tumor Effect of CT-322 as an Adnectin Inhibitor of Vascular Endothelial Growth Factor Receptor-2. (2010)
-
Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug therapy assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma (2010)
-
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer (2010)
|
| |
|
Pre/Non Reviewed Papers, Proceedings: 248 (992 / 0)
|
-
Anti-Tumor Effect of CT-322 as an Adnectin Inhibitor of Vascular Endothelial Growth Factor Receptor-2. (2010)
-
Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug therapy assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma (2010)
-
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer (2010)
|
| |
|
Membership in Professional Societies: 0 (0 / 0)
|
|
| |
|
White Papers: 0 (0 / 0)
|
|
| |
| Registered on BiotechScienceNews: 1 |
How We Rank
